162 related articles for article (PubMed ID: 38026958)
1. Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for
Cheng J; Fan C; Huang K; Zhai L; Wang H; Xie D; Cai Y; Li Z; Bai Q; Wang P; Ding H
Front Pharmacol; 2023; 14():1272744. PubMed ID: 38026958
[No Abstract] [Full Text] [Related]
2. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of
Niu M; Zhou Y; Xie Y; Li X; Tian Y; Yao L; Li X; Gao H; Bai F
Front Pharmacol; 2022; 13():771876. PubMed ID: 35571120
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy
Mei H; Guo Y; Zhao JT; Yang J; Sun WJ; Zhang DK; He P; Shi G; Su NY; Han R; Lan CH
Therap Adv Gastroenterol; 2022; 15():17562848221142925. PubMed ID: 36600686
[TBL] [Abstract][Full Text] [Related]
4. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
[TBL] [Abstract][Full Text] [Related]
5. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for
Yang Q; He C; Hu Y; Hong J; Zhu Z; Xie Y; Shu X; Lu N; Zhu Y
Front Pharmacol; 2023; 14():1096103. PubMed ID: 36817141
[No Abstract] [Full Text] [Related]
6. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
7. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
Macedo Silva V; Lima Capela T; Freitas M; Boal Carvalho P; Magalhães J; Cotter J
Helicobacter; 2023 Jun; 28(3):e12962. PubMed ID: 36828647
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
[TBL] [Abstract][Full Text] [Related]
9. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
[TBL] [Abstract][Full Text] [Related]
10. Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Zhang XD; Zhang DY; Chen RX; Chen SJ; Chen C; Zeng F; Huang SM; Li D; Bai FH
BMC Gastroenterol; 2023 Jul; 23(1):249. PubMed ID: 37488516
[TBL] [Abstract][Full Text] [Related]
11. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
[TBL] [Abstract][Full Text] [Related]
12. The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for
Shen C; Li C; Lv M; Dai X; Gao C; Li L; Zhang Q; Pan W; Liu C; Han S; Zhang Y; Ding S; Deng H; Yao Y; Xu J; Wei M; Shi H; Yuan P; Yang X; Jian Y; Shan J; Liu Y; Chen Z; Deng X; Liu F; Deng L; Zhong X; Li H; He S; Chen L; Liu G; Xu H; Zhong Y; Shi H; Ren J;
Ann Med; 2022 Dec; 54(1):426-435. PubMed ID: 35098820
[TBL] [Abstract][Full Text] [Related]
13. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
15. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
Zhang C; Zhang J; Cheng YJ
Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
[TBL] [Abstract][Full Text] [Related]
16. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
18. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
19. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of vonoprazan-amoxicillin dual therapy for
Wang X; Teng G; Dong X; Dai Y; Wang W
Therap Adv Gastroenterol; 2023; 16():17562848231190976. PubMed ID: 37664169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
